The Reason Why Samchundang Pharmaceutical's Stock Plummeted 25% Despite Securing a $100 Million Contract for GLP-1 Generics in the U.S.
\n Samchundang Pharm Ventures into the U.S. GLP-1 Generic Market: How Oral Semaglutide Could Revolutionize the Game GLP-1 has emerged as a key keyword in the global diabetes and obesity treatment market. Among them, South Korean pharmaceutical company Samchundang Pharm has pulled out the card to enter the U.S. market by expanding the trend—previously dominated by injectable drugs—into the realm of oral semaglutide (Rybelsus, Wegovy) . So what kind of change could the “challenge by a domestic company in the U.S. oral GLP-1 generic market” bring to the industry? The Core of Samchundang Pharm’s U.S. Deal: Betting on Oral Semaglutide Generics Samchundang Pharm has secured a foothold for commercialization in the U.S. by signing an exclusive license agreement with its American partner for oral semaglutide generics . The disclosed terms convey a clear message: Milestone payments totaling $100 million Targets: Rybelsus generics (1.5–14 mg), Wegovy generics (1.5–...